

February 5, 2016



Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016

-Also Presenting at Bio CEO & Investor Conference on February 9, 2016-

SAN DIEGO, Feb. 5, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.



The presentation will be made available to the public via live audio webcast which can be accessed by visiting the investor relations section of Aethlon Medical's corporate website at <http://www.aethlonmedical.com>. The webcast will be available for replay approximately one hour after the conclusion of the live event. The panel discussion will not be webcast.

Aethlon Medical will also be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016. A webcast of the presentation can be accessed by visiting the investor relations section of Aethlon Medical's corporate website at <http://www.aethlonmedical.com>.

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The

Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens. The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients. The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

Contacts:

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com

Photo - <https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-source-capital-groups-2016-disruptive-growth--healthcare-conference-on-february-10-2016-300215098.html>

SOURCE Aethlon Medical, Inc.